Provectus Biopharmaceuticals, Inc. Share Price

PVCT

US74373P1084

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 20:21:20 08/07/2026 BST			5-day change	1st Jan Change
0.0697 ^USD	+4.03%		+0.43%	+24.69%

07-07	Provectus Biopharmaceuticals, Inc. Highlights Peer-Reviewed Study Demonstrating Opposing Mechanistic Effects Of Rose Bengal Sodium At The Same Dose	CI
06-25	Provectus Biopharmaceuticals, Inc. Launches Veripure Open Science Program For Medical Research Access To PV-10	CI

Valuation: Provectus Biopharmaceuticals, Inc.

Market Cap	28.16M 24.67M 22.74M 21.03M 39.9M 2.69B 40.64M 273M 106M 1.32B 106M 103M 4.58B	P/E 2024	-10.6x	P/E 2025	-4.33x
Enterprise Value	30.89M 27.06M 24.94M 23.06M 43.77M 2.95B 44.58M 299M 116M 1.45B 116M 113M 5.02B	EV / Sales 2024	86,451,912x	EV / Sales 2025	78,013,766x
Free-Float	92.52%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Chart: Provectus Biopharmaceuticals, Inc.

Dynamic Chart

Latest news : Provectus Biopharmaceuticals, Inc.

07-07	Provectus Biopharmaceuticals, Inc. Highlights Peer-Reviewed Study Demonstrating Opposing Mechanistic Effects Of Rose Bengal Sodium At The Same Dose	CI
06-25	Provectus Biopharmaceuticals, Inc. Launches Veripure Open Science Program For Medical Research Access To PV-10	CI
06-19	Provectus Biopharmaceuticals, Inc. - Shareholder/Analyst Call
05-18	Provectus Biopharmaceuticals reports oral pv-10 anti-tumor activity in preclinical bladder cancer study	RE
05-18	Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity In Preclinical Bladder Cancer Study	CI
05-14	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-04	Provectus Biopharmaceuticals, Inc. Presents New Data on Rose Bengal Photodynamic Antimicrobial Therapy At Arvo 2026	CI
04-02	Provectus Biopharmaceuticals Highlights Preclinical Evidence Of PV-10-Mediated Immune Modulation In Burn Wound Healing	CI
03-26	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-25	Provectus Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
11-13	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
09/10/25	Provectus Biopharmaceuticals Positions Pv-10 as Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel Sting-Pathway Activation for Improving Hepatitis B Vaccine Efficacy	CI
29/09/25	Provectus Biopharmaceuticals initiates preclinical study of oral PV-10	RE

More news

Last Transcript: Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc. - Shareholder/Analyst Call

06-19

More transcripts

Press Releases: Provectus Biopharmaceuticals, Inc.

07-07	Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose	AQ
06-30	Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections	AQ
06-25	Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)	AQ
06-08	Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders	AQ
05-18	Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End	AQ

More press releases

Managers and Directors: Provectus Biopharmaceuticals, Inc.

Manager	Title	Age	Since
Edward Pershing CEO	Chief Executive Officer	73	15/04/2024
Eric Wachter CTO	Chief Tech/Sci/R&D Officer	62	14/05/2012
Heather Raines DFI	Director of Finance/CFO	59	24/03/2019

Director	Title	Age	Since
Dominic Rodrigues CHM	Chairman	57	02/04/2017
John Lacey BRD	Director/Board Member	78	26/04/2018
Edward Pershing CHM	Chairman	73	26/04/2018

More insiders

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Companyâ€™s lead molecule is named rose bengal sodium (RBS). The Companyâ€™s small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Companyâ€™s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo proof-of-concept drug discovery programs in oncology, hematology, wound healing, and animal health, and in vitro drug discovery programs in infectious diseases and tissue regeneration and repair.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
08/07/26	US$0.0697	+4.03%	352,220
07/07/26	US$0.0670	-2.62%	378,599
06/07/26	US$0.0688	-0.29%	41,590
02/07/26	US$0.0690	-0.87%	66,450
01/07/26	US$0.0696	+0.29%	138,519

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Stock Market
Stocks
PVCT Stock

Google lets you customize your preferred sources.

Choose MarketScreener

1 day	+4.03%
1 week	+0.43%
Current month	+0.43%
1 month	+10.63%
3 months	+22.07%
6 months	+9.25%
Current year	+24.69%

1 week	0.06	0.07
1 month	0.06	0.07
Current year	0.04	0.07
1 year	0.04	0.1
3 years	0.04	0.22
5 years	0.03	0.22
10 years	0.01	0.35

Date	Insider	Type	Main position	Quantity	% Market Cap.
06-29	John Lacey	Free	Director	48,917	0.5182%
06-29	Edward Pershing	Free	Chief Executive Officer	45,860	0.4858%
06-29	Dominic Rodrigues	Free	Chairperson	45,860	0.4858%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PROVECTUS BIOPHARMACEUTICALS, INC.	+4.03%	+0.43%	-7.07%	-41.97%	28.16M
ARGENX SE	-1.53%	-1.43%	+71.67%	+129.70%	57.72B
WUXI APPTEC CO., LTD.	-2.45%	-7.32%	+65.23%	+83.15%	52.65B
INSMED INCORPORATED	+3.27%	+9.29%	+20.20%	+486.76%	24.46B
BIONTECH SE	-0.81%	+0.52%	-15.01%	-12.47%	23.84B
WUXI BIOLOGICS (CAYMAN) INC.	-3.05%	+3.06%	+42.36%	-5.66%	19.28B
GENMAB A/S	-0.24%	+5.40%	+44.65%	-26.41%	17.8B
PHARMAESSENTIA CORPORATION	+2.34%	+14.18%	+220.96%	+380.99%	17.29B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-6.73%	+9.90%	+36.04%	-	15.28B
EXELIXIS, INC.	-1.70%	+3.12%	+27.06%	+190.57%	14.35B
Average	-0.69%	+4.33%	+50.61%	+131.63%	24.27B
Weighted average by Cap.	-1.26%	+2.71%	+58.00%	+141.64%

	2024	2025
Net sales	0.62 0.54 0.5 0.46 0.87 58.96 0.89 5.98 2.33 28.91 2.32 2.27 100.31	0.34 0.29 0.27 0.25 0.48 32.11 0.49 3.25 1.27 15.74 1.26 1.23 54.63
Net income	-4.76M -4.17M -3.85M -3.56M -6.75M -455M -6.87M -46.12M -17.96M -223M -17.88M -17.49M -774M	-5.43M -4.76M -4.39M -4.06M -7.7M -519M -7.84M -52.59M -20.48M -254M -20.39M -19.95M -883M
Net Debt	2.88M 2.52M 2.32M 2.15M 4.08M 275M 4.15M 27.86M 10.85M 135M 10.8M 10.57M 468M	2.73M 2.39M 2.2M 2.04M 3.87M 261M 3.94M 26.41M 10.28M 128M 10.24M 10.02M 443M

Provectus Biopharmaceuticals, Inc. Share Price

Stocks

PVCT

US74373P1084

Biotechnology & Medical Research

Valuation: Provectus Biopharmaceuticals, Inc.

Chart: Provectus Biopharmaceuticals, Inc.

Latest news : Provectus Biopharmaceuticals, Inc.

Last Transcript: Provectus Biopharmaceuticals, Inc.

Press Releases: Provectus Biopharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Provectus Biopharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates